Pasithea Therapeutics (KTTA) Assets Average (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Assets Average of $58.3 million for Q1 2026, up 57.84% sequentially from $36.9 million in Q4 2025, and up 279.5% YoY from $15.4 million in Q1 2025.
Pasithea Therapeutics (KTTA) Assets Average (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Assets Average for 6 years, with the latest figure at $58.3 million in Q1 2026.
- Quarterly Assets Average rose 279.5% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 279.5% YoY) and the FY2025 annual result came in at $38.2 million, up 80.9% from the prior year.
- Assets Average climbed to $58.3 million in Q1 2026 per KTTA's latest filing, from $36.9 million in the prior quarter.
- Over five years, Assets Average peaked at $58.3 million in Q1 2026 and troughed at $15.3 million in Q3 2025.
- A 5-year average of $33.6 million and a median of $34.4 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2026: Assets Average plunged 50.03% in 2024, then soared 279.5% in 2026.
- Over 5 years, Assets Average stood at $47.4 million in 2022, then sank by 40.1% to $28.4 million in 2023, then slumped by 38.88% to $17.4 million in 2024, then jumped by 112.87% to $36.9 million in 2025, then soared by 57.84% to $58.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $58.3 million, $36.9 million, and $15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | 54.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.30 Mn |
| Dec 31, 2025 | 36.94 Mn |
| Sep 30, 2025 | 15.32 Mn |
| Jun 30, 2025 | 15.83 Mn |
| Mar 31, 2025 | 15.36 Mn |
| Dec 31, 2024 | 17.35 Mn |
| Sep 30, 2024 | 18.15 Mn |
| Jun 30, 2024 | 20.04 Mn |
| Mar 31, 2024 | 24.26 Mn |
| Dec 31, 2023 | 28.39 Mn |
| Sep 30, 2023 | 34.40 Mn |
| Jun 30, 2023 | 40.10 Mn |
| Mar 31, 2023 | 43.61 Mn |
| Dec 31, 2022 | 47.39 Mn |
| Sep 30, 2022 | 51.32 Mn |
| Jun 30, 2022 | 52.05 Mn |
| Mar 31, 2022 | 52.20 Mn |
| Dec 31, 2021 | 37.18 Mn |